Poster exhibition
Antiviral therapy and resistance

Programme

• • Poster
  • P 065

  Nanobody-engineered nuclear E3-ubiquitin ligase adaptor effectively degrades PRRS Virus RdRp through lysosomal pathway in cytoplasm

  • Professor Fandan Meng (Harbin / CN)

   Antiviral therapy and resistance
• • Poster
  • P 066

  In vitro profiling of the antiviral peptide TAT-I24

  • Dr. Hanna Harant (Vienna / AT)

   Antiviral therapy and resistance
• • Poster
  • P 067

  An RNA replicon system to investigate promising inhibitors of feline coronavirus

  • Kimberly Schmied (Bern / CH)

   Antiviral therapy and resistance
• • Poster
  • P 068

  Zapnometinib – A host targeted MEK1/2-inhibitor with broad anti-SARS-CoV-2 activity, strong synergism with licensed drugs and a high barrier towards emergence of resistance

  • Dr. André Schreiber (Münster / DE)

   Antiviral therapy and resistance
• • Poster
  • P 069

  The role of gut bacteria mediated metabolites in anti-viral immune responses

  • Magdalena Siller (Vienna / AT)

   Antiviral therapy and resistance
• • Poster
  • P 070

  Antiviral activity of small molecules against coronaviruses

  • Natalie M. Köhler (Hannover / DE)

   Antiviral therapy and resistance
• • Poster
  • P 071

  Small molecule antiviral for Dengue Virus selectively inhibits the ER co-translational translocation of the flaviviral polyprotein

  • Dr. Marijke Verhaegen (Leuven / BE)

   Antiviral therapy and resistance
• • Poster
  • P 072

  Chimeric antigen receptor T cells to fight cytomegalovirus infections

  • Sabrina Kübel (Erlangen / DE)

   Antiviral therapy and resistance
• • Poster
  • P 073

  Mechanisms of antiviral action of the influenza defective interfering particle "OP7"

  • Dr. Julita Piasecka (Magdeburg / DE)

   Antiviral therapy and resistance
• • Poster
  • P 074

  Nucleoside analogues and inhibitors of pyrimidine synthesis synergize to suppress Influenza A virus replication

  • Leon Schrell (Göttingen / DE)

   Antiviral therapy and resistance
• • Poster
  • P 075

  The herpesviral DNA-polymerase associated factor as a putative drug target

  • Marie-Sophie Schulze (Hannover / DE)

   Antiviral therapy and resistance
• • Poster
  • P 076

  Novel targeting strategies of the cytomegalovirus nuclear egress complex based on covalently binding warhead compounds

  • Julia Tillmanns (Erlangen / DE)

   Antiviral therapy and resistance
• • Poster
  • P 078

  Preclinical development of host-directed dual-target small molecule inhibitors as broad-spectrum antivirals

  • Dr. Alexandra Herrmann (Gräfelfing / DE)

   Antiviral therapy and resistance
• • Poster
  • P 079

  The spike receptor-binding motif G496S substitution determines the replication fitness of SARS-CoV-2 Omicron sublineage

  • Dr. Ronghui Liang (Hong Kong / HK)

   Antiviral therapy and resistance
• • Poster
  • P 080

  Defective interfering particles of influenza A virus as broad-spectrum antivirals

  • Dr. Sascha Young Kupke (Magdeburg / DE)

   Antiviral therapy and resistance
• • Poster
  • P 081

  Enhancing VIRIP-Derived HIV-1 gp41 fusion peptide inhibitors through advanced atomistic modeling

  • Dr. Christoph Jung (Eggenstein-Leopoldshafen / DE)

   Antiviral therapy and resistance
• • Poster
  • P 082

  Ophthalmic Co-Culture meets in vitro 3D-Models in virology research

  • Marco Bechtel (Frankfurt am Main / DE)

   Antiviral therapy and resistance
• • Poster
  • P 083

  Differential sensitivity of SARS-CoV-2 virus variants to the antiviral peptide TAT-I24

  • Eva Kicker (Graz / AT)

   Antiviral therapy and resistance
• • Poster
  • P 084

  Discovery and characterization of Trypstatin as inhibitor of TMPRSS2 and respiratory viral infection

  • Jan Lawrenz (Ulm / DE)

   Antiviral therapy and resistance
• • Poster
  • P 085

  Development of human pan-hantavirus antibodies for treatment of hantavirus-associated diseases

  • Dr. Nooran Elleboudy (Berlin / DE)

   Antiviral therapy and resistance
• • Poster
  • P 086

  Discovery of novel autophagy inducing anti-viral peptides derived from the human peptidome

  • Dennis Freisem (Ulm / DE)

   Antiviral therapy and resistance
• • Poster
  • P 087

  CRISPR Cas13 as an antiviral tool against respiratory RNA viruses

  • Anna Carolina Henkel (Hannover / DE)

   Antiviral therapy and resistance
• • Poster
  • P 088

  PROTAC-mediated targeted protein degradation of the SARS-CoV-2 main protease using an allosteric warhead

  • Christopher Veeck (Marburg / DE)

   Antiviral therapy and resistance
• • Poster
  • P 089

  Host cell factors as antiviral targets to limit adenovirus infection

  • Dr. Sebastian Schloer (Hamburg / DE)

   Antiviral therapy and resistance
• • Poster
  • P 090

  Influence of AAV capsid tropism on transcriptional activity of the delivered vector construct

  • Jannik T. Wagner (Erlangen / DE)

   Antiviral therapy and resistance
• • Poster
  • P 091

  A comprehensive study of SARS-CoV-2 main protease (M^pro) inhibitor-resistant mutants selected in a VSV-based system

  • Francesco Costacurta (Innsbruck / AT)

   Antiviral therapy and resistance
• • Poster
  • P 092

  Optimization of mRNA encapsulated Lipid nanoparticles (LNPs) for in vivo administration of monoclonal antibodies

  • Hanife Dinc (Erlangen / DE)

   Antiviral therapy and resistance
• • Poster
  • P 093

  Inhibition and specific targeting of infected cells by VSV particles carrying viral receptors

  • Dr. Fabian Zech (Ulm / DE)

   Antiviral therapy and resistance
• • Poster
  • P 094

  Thioxothiazolo[3,4-a]quinazoline derivatives inhibit the human cytomegalovirus alkaline nuclease

  • Andrea Salvatore Albanese (Hamburg / DE)

   Antiviral therapy and resistance
• • Poster
  • P 095

  Pan-serotype dengue virus inhibitor JNJ-A07 targets the NS4A-2K-NS4B interaction with NS2B/NS3 and blocks de novo formation of replication organelles

  • Dr. Dominik Kiemel (Heidelberg / DE)

   Antiviral therapy and resistance
• • Poster
  • P 096

  In vitro and in vivo effects of Pelargonium sidoides DC. root extract EPs^® 7630 and selected constituents against SARS-CoV-2 B.1, Delta AY.4/AY.117 and Omicron BA.2

  • Jackson Emanuel (Berlin / DE)

   Antiviral therapy and resistance
• • Poster
  • P 097

  Multimerization of mAbs and their Fab derivatives by functionalizing DNA-Origami Nanoshells improves Influenza A H1N1 Neutralization in vitro

  • Michael Schachtner (Regensburg / DE)

   Antiviral therapy and resistance
• • Poster
  • P 098

  Design of peptides inhibiting SAMHD1 activity

  • Aleksandra Mitric (Erlangen / DE)

   Antiviral therapy and resistance
• • Poster
  • P 099

  Exploring HIV-1 splice site susceptibility to splicing inhibitors as a potential therapeutic strategy to interfere with viral replication

  • Laura Peter (Düsseldorf / DE)

   Antiviral therapy and resistance
• • Poster
  • P 100

  Deciphering the persistence of bornaviruses

  • Sebastian Giese (Freiburg / DE)

   Antiviral therapy and resistance
• • Poster
  • P 101

  Geno2pheno: De Novo Recombination detection of A6 subtypes

  • Dr. Martin Pirkl (Cologne / DE)

   Antiviral therapy and resistance
• • Poster
  • P 102

  Design of dual chimeric virus to test cross-resistance to or synergy of coronavirus inhibitors

  • Dr. Emmanuel Heilmann (Innsbruck / AT)

   Antiviral therapy and resistance
• • Poster
  • P 103

  The kidney as extrahepatic site of Hepatitis E Virus replication

  • Dr. André Gömer (Bochum / DE)

   Antiviral therapy and resistance
• • Poster
  • P 104

  Development of Sudan ebolavirus VP40 inhibitors via structure-guided drug design

  • Dr. Anke-Dorothee Werner (Marburg / DE)

   Antiviral therapy and resistance
• • Poster
  • P 105

  Limited high-throughput screening compatibility of the phenuivirus cap-binding domain

  • Janna Scherf (Hamburg / DE)

   Antiviral therapy and resistance
• • Poster
  • P 106

  The BRD4- selective small molecule ZL0580 interferes with protein expression of transcription elongation factor ELL2 and HTLV-1 Tax

  • Abarna Baheerathan (Erlangen / DE)

   Antiviral therapy and resistance
• • Poster
  • P 107

  Novel small-molecule inhibitors targeting the entry of the respiratory syncytial virus

  • Leila Issmail (Leipzig / DE)

   Antiviral therapy and resistance
• • Poster
  • P 108

  Preclinical studies revealed the high efficacy of immunotherapy by equine polyclonal antibodies against novel SARS-CoV-2 variants of concern

  • Dr. Maksym Kitsera (Hamburg / DE)

   Antiviral therapy and resistance
• • Poster
  • P 109

  Fate of Spike expressed from genetic vaccines and produced during SARS-CoV-2 infection: A unifying pathogenetic link to some pathologies following vaccination or observed in COVID-19?

  • Dr. Lea Krutzke (Ulm / DE)

   Antiviral therapy and resistance
• • Poster
  • P 110

  Cyclosporin A inhibits VSV infection by Interferon-λ mediated induction of CMPK2

  • Lars Meier (Marburg / DE)

   Antiviral therapy and resistance
• • Poster
  • P 111

  Characterizing HCMV pUL77 as potential druggable target

  • Jan Marc Beneke (Lübeck / DE)

   Antiviral therapy and resistance
• • Poster
  • P 112

  Metabolic modeling elucidates phenformin and atpenin A5 as broad-spectrum antiviral drugs

  • Dr. Raphael Jami (Tuebingen / DE)

   Antiviral therapy and resistance
• • Poster
  • P 113

  Semen enhances transmitted/founder HIV-1 infection and only marginally reduces antiviral activity of broadly neutralizing antibodies

  • Pascal von Maltitz (Ulm / DE)

   Antiviral therapy and resistance
• • Poster
  • P 114

  ATO (Arsenic Trioxide) impacts hepatitis B virus core nuclear localization and efficiently interferes with HBV infection

  • Professor Sabrina Schreiner (Freiburg / DE)

   Antiviral therapy and resistance
• • Poster
  • P 115

  Synergistic interference with SARS-CoV-2 replication by Monupiravir-derived N4 hydroxycytidine and inhibitors of CTP synthetase

  • Antje Dickmanns (Göttingen / DE)

   Antiviral therapy and resistance
• • Poster
  • P 116

  Analysis of Fab fragments from neutralizing antibodies for prevention of cell-associated spread of human cytomegalovirus

  • Kerstin Laib Sampaio (Ulm / DE)

   Antiviral therapy and resistance
• • Poster
  • P 117

  Elevating antiviral testing standards through advanced multi-organ-chips

  • Dr. Susann Kummer (Berlin / DE)

   Antiviral therapy and resistance
• • Poster
  • P 118

  Highly specific SARS-CoV-2 main protease (M^pro) mutations against the clinical antiviral ensitrelvir selected in a safe, VSV-based system

  • Stefanie Rauch (Innsbruck / AT)

   Antiviral therapy and resistance
• • Poster
  • P 119

  The antiviral effect of Anagallis arvensis L. saponins on HSV-1 correlates with their fusion-inhibitory activity

  • Nica Classen (Muenster / DE)

   Antiviral therapy and resistance